Consun Pharmaceutical Group (HKG:1681) reported a 16.1% increase in profit attributable to equity shareholders for 2024 to 910.5 million yuan from 784.5 million yuan a year earlier, according to a Wednesday filing with the Hong Kong bourse.
Earnings per share were 1.09 yuan, an 11.2% increase from 0.98 yuan the previous year.
Revenue increased by 14.6% to 2.97 billion yuan from 2.59 billion yuan in the prior year.
The board recommended a final dividend of HK$0.30 per share.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments